Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
In sepsis and septic shock, the host response is characterized by a complex of
immune-inflammatory reactions; triggered and activated by microbial components. These
reactions are controlled by a balance of pro-inflammatory cytokines and anti-inflammatory
cytokines. The imbalance of this immune response is a source of organ dysfunction; major
prognostic factor during septic condition. This pretext has created the need for therapies
aimed to modulate the overstated of host response. During the past 2 decades, macrolide
molecules proved interest to be immunomodulatory agents; due beyond their antibacterial
activity. Their regulatory role in the production of cytokines was demonstrated in the
management of severe acute community pneumonia.
The investigators hypothesize that the adjunction of macrolides to standard therapy in
patients with sepsis or septic shock is associated to a favorable immunomodulatory and
clinical effects.